The Cutaneous Connection: Episode 30- Impact of the JAK Inhibitor Approval Delays


Mark Lebwohl, MD, takes a deep dive in the recent delay in approval for multiple JAK inhibitor drugs for treatment of inflammatory skin conditions such as psoriasis and atopic dermatitis. He also discusses the impact of the delay, as well as the benefits of JAK inhibitors for inflammatory skin diseases, and an outlook for the future of this drug class.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.